FDA Approves LungFX Device to Rescue Donor Lungs Rejected for Transplant
United Therapeutics wins FDA approval for LungFX, a device that keeps donor lungs viable outside the body for transplant reassessment.
Summary
The FDA has approved LungFX, a device from United Therapeutics that uses ex vivo lung perfusion to keep donor lungs alive and functioning outside the body. Many donor lungs are initially deemed unsuitable for transplant but may still be viable. LungFX warms and ventilates these rejected lungs to reassess whether they can be safely transplanted into adults awaiting a first lung transplant. The technology builds on over 1,100 prior procedures using similar devices, with 600 lungs successfully accepted for transplant. However, a pivotal clinical study did not meet its 12-month survival target and showed higher mortality in patients receiving EVLP-assessed lungs compared to standard controls, raising important questions about long-term outcomes.
Detailed Summary
Lung transplantation is one of the most life-extending interventions available to people with end-stage pulmonary disease, yet donor organ shortages remain a critical barrier. Many procured lungs are discarded as unsuitable before ever reaching a recipient. Technologies that can recover and reassess these organs have the potential to dramatically expand the transplant pool and save lives.
United Therapeutics has received FDA premarket approval for its LungFX device, designed for centralized ex vivo lung perfusion. The device maintains donor lungs in a warm, perfused, and ventilated state outside the body, allowing clinicians to evaluate whether organs initially stored in cold preservation solution are actually viable for transplantation. It is indicated for adults aged 18 and older awaiting their first lung transplant.
The company reports that its subsidiary Lung Bioengineering has already performed over 1,100 EVLP procedures using other approved systems, with 600 of those lungs ultimately accepted for transplant. LungFX is expected to be added to clinical services in 2027, potentially expanding the number of usable donor lungs and shortening wait times for patients.
However, significant caveats accompany the approval. The pivotal CLES clinical study did not meet its pre-specified 12-month survival performance goal. Patients receiving EVLP-assessed lungs showed higher rates of both overall and graft-related mortality at 12 months compared to non-EVLP controls. Long-term effects on recipient survival and graft function remain uncertain, and the FDA specifies that only qualified personnel should operate the device.
For the longevity-focused community, this approval highlights both the promise and the complexity of organ bioengineering as a life-extension tool. The technology addresses a genuine bottleneck in transplant medicine, but the survival data demands careful scrutiny before widespread adoption. Further long-term studies will be essential to determine whether LungFX ultimately improves or compromises recipient outcomes.
Key Findings
- FDA approved LungFX for ex vivo lung perfusion to reassess donor lungs initially rejected for transplant.
- Over 1,100 EVLP procedures performed previously; 600 lungs accepted for transplant using similar devices.
- Pivotal CLES study did not meet its 12-month survival goal; EVLP patients showed higher mortality than controls.
- Total cumulative preservation time must not exceed 20 hours; device intended for adults 18 and older only.
- LungFX is expected to enter clinical service at Lung Bioengineering in 2027.
Methodology
This is a news report summarizing an FDA approval announcement from United Therapeutics. Evidence basis includes regulatory approval documentation and reported outcomes from the CLES pivotal trial. No peer-reviewed publication of the trial data is cited directly.
Study Limitations
The pivotal clinical trial did not meet its primary survival endpoint, and full trial data have not been published in peer-reviewed literature. Long-term graft and survival outcomes remain uncertain. Readers should consult the FDA approval documentation and await publication of the CLES trial results for a complete evidence assessment.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: